1651 related articles for article (PubMed ID: 26598747)
1. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW
J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747
[TBL] [Abstract][Full Text] [Related]
2. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
3. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.
Gadgeel SM; Shaw AT; Govindan R; Gandhi L; Socinski MA; Camidge DR; De Petris L; Kim DW; Chiappori A; Moro-Sibilot DL; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; Yang JC; Han JY; Bordogna W; Golding S; Zeaiter A; Ou SI
J Clin Oncol; 2016 Dec; 34(34):4079-4085. PubMed ID: 27863201
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Gandhi L; Ou SI; Shaw AT; Barlesi F; Dingemans AC; Kim DW; Camidge DR; Hughes BGM; Yang JC; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S
Eur J Cancer; 2017 Sep; 82():27-33. PubMed ID: 28646771
[TBL] [Abstract][Full Text] [Related]
6. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
7. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT; Gandhi L; Gadgeel S; Riely GJ; Cetnar J; West H; Camidge DR; Socinski MA; Chiappori A; Mekhail T; Chao BH; Borghaei H; Gold KA; Zeaiter A; Bordogna W; Balas B; Puig O; Henschel V; Ou SI;
Lancet Oncol; 2016 Feb; 17(2):234-242. PubMed ID: 26708155
[TBL] [Abstract][Full Text] [Related]
8. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
9. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nishio M; Nakagawa K; Mitsudomi T; Yamamoto N; Tanaka T; Kuriki H; Zeaiter A; Tamura T
Lung Cancer; 2018 Jul; 121():37-40. PubMed ID: 29858024
[TBL] [Abstract][Full Text] [Related]
10. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Novello S; Mazières J; Oh IJ; de Castro J; Migliorino MR; Helland Å; Dziadziuszko R; Griesinger F; Kotb A; Zeaiter A; Cardona A; Balas B; Johannsdottir HK; Das-Gupta A; Wolf J
Ann Oncol; 2018 Jun; 29(6):1409-1416. PubMed ID: 29668860
[TBL] [Abstract][Full Text] [Related]
11. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Larkins E; Blumenthal GM; Chen H; He K; Agarwal R; Gieser G; Stephens O; Zahalka E; Ringgold K; Helms W; Shord S; Yu J; Zhao H; Davis G; McKee AE; Keegan P; Pazdur R
Clin Cancer Res; 2016 Nov; 22(21):5171-5176. PubMed ID: 27413075
[TBL] [Abstract][Full Text] [Related]
13. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S; Peters S; Mok T; Shaw AT; Kim DW; Ou SI; Pérol M; Wrona A; Novello S; Rosell R; Zeaiter A; Liu T; Nüesch E; Balas B; Camidge DR
Ann Oncol; 2018 Nov; 29(11):2214-2222. PubMed ID: 30215676
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non-small-cell lung cancer with or without prior crizotinib therapy.
Hida T; Nakagawa K; Seto T; Satouchi M; Nishio M; Hotta K; Takahashi T; Ohe Y; Takeda K; Tatsuno M; Asakawa T; Shimada T; Tanaka T; Tamura T
Cancer Sci; 2016 Nov; 107(11):1642-1646. PubMed ID: 27566263
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
16. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Gadgeel S; Shaw AT; Barlesi F; Crinò L; Yang JC; Dingemans AC; Kim DW; de Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou SI
Br J Cancer; 2018 Jan; 118(1):38-42. PubMed ID: 29149104
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of ALK-positive NSCLC progressing on crizotinib.
Metro G; Tazza M; Matocci R; Chiari R; Crinò L
Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
[TBL] [Abstract][Full Text] [Related]
18. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
19. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib.
Sakamoto H; Yanagitani N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Yoshida H; Amino Y; Ariyasu R; Uchibori K; Kitazono S; Tasaka S; Nishio M
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1414. PubMed ID: 33960745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]